Nevro (NYSE:NVRO) had its target price raised by Canaccord Genuity from $46.00 to $62.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have a buy rating on the medical equipment provider’s stock.
NVRO has been the topic of several other reports. Zacks Investment Research cut Nevro from a buy rating to a hold rating in a report on Thursday, January 10th. Morgan Stanley reduced their target price on Nevro from $43.00 to $38.00 and set an underweight rating on the stock in a report on Wednesday, January 2nd. Bank of America raised Nevro from a neutral rating to a buy rating and boosted their price objective for the stock from $50.00 to $70.00 in a research note on Wednesday. BMO Capital Markets cut Nevro from an outperform rating to a market perform rating in a research note on Friday, February 22nd. Finally, UBS Group started coverage on Nevro in a research note on Tuesday, November 27th. They set a sell rating and a $35.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. Nevro currently has an average rating of Hold and an average price target of $62.67.
Shares of NVRO stock opened at $62.05 on Wednesday. Nevro has a 12-month low of $34.75 and a 12-month high of $94.34. The company has a current ratio of 7.11, a quick ratio of 5.64 and a debt-to-equity ratio of 0.62.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MUFG Securities EMEA plc bought a new stake in Nevro during the fourth quarter worth approximately $4,721,000. Geode Capital Management LLC increased its stake in Nevro by 9.3% during the fourth quarter. Geode Capital Management LLC now owns 308,995 shares of the medical equipment provider’s stock worth $12,016,000 after acquiring an additional 26,356 shares during the last quarter. Norges Bank bought a new stake in Nevro during the fourth quarter worth approximately $36,675,000. HRT Financial LLC increased its stake in Nevro by 103.0% during the fourth quarter. HRT Financial LLC now owns 7,416 shares of the medical equipment provider’s stock worth $288,000 after acquiring an additional 3,762 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Nevro by 31.2% during the fourth quarter. Legal & General Group Plc now owns 12,886 shares of the medical equipment provider’s stock worth $502,000 after acquiring an additional 3,065 shares during the last quarter.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.